BioSpectrum the business of Bio & Health Sciences ASIA EDITION

Selventa, Seegene to accelerate personalized medicine

April 24, 2013 | News | By BioSpectrum Bureau



Singapore: Seoul-based Seegene and Selventa entered into a strategic collaboration to develop novel molecular diagnostics including autoimmune, cancer and infectious diseases. The synergistic combination of Selventa's Systems Diagnostics (SysDx) multi-omic analytics platform and Seegene's TOCE and DPO multiplex PCR technology will result in powerful new MoDx that accelerate the adoption of personalized medicine in major classes of disease.

Selventa' SysDx works by analyzing a holistic range of a patient's molecular information to identify a panel of "multi-omic" biomarkers that can accurately diagnose a patient's disease and response or non-response to a therapy. By leveraging a powerful, first-in-class multiplexing technology, SysDx's multi-omic biomarker approach can be the basis for a range of high value MoDx.

Seegene's qTOCE technology provides real-time simultaneous detection and quantification of multiple targets in a single channel. qTOCE can work with any qPCR instrument to differentiate as many as seven targets per channel from a single sample, in a single reaction. qTOCE enables multiplex assay development across a wide range of applications, including high-multiplex quantitative real-time PCR and highly selective mutational analysis.

"We are excited to collaborate with Seegene, a leading molecular diagnostic technology innovator," said Dr David de Graaf, president and CEO, Selventa. "Seegene's world-class detection technology and assay development in combination with our SysDx platform can result in a wide range of novel MoDx with high clinical utility."

"Selventa's SysDx platform is a breakthrough approach to biomarker identification that has the potential to vastly improve patient diagnosis and care," said Dr Jong-Yoon Chun, founder, CTO and CEO of Seegene. "Our multiplex PCR technology detecting a wide range of SysDx-derived biomarkers can facilitate better patient diagnostics, improved patient care, and reduced healthcare costs."